Scarica l'app Stockscreener
16.41
2.26%
-0.38
Pre-mercato:
16.53
0.12
+0.73%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$16.79
Aprire:
$16.9
Volume 24 ore:
395.74K
Relative Volume:
1.02
Capitalizzazione di mercato:
$444.50M
Reddito:
$157.75M
Utile/perdita netta:
$-29.73M
Rapporto P/E:
-14.15
EPS:
-1.16
Flusso di cassa netto:
$-21.00M
1 W Prestazione:
-1.08%
1M Prestazione:
+6.01%
6M Prestazione:
-31.02%
1 anno Prestazione:
-49.92%
Intervallo 1D:
$16.32
$17.37
Intervallo di 1 settimana:
$16.07
$17.95
Portata 52W:
$14.30
$45.00
Arcturus Therapeutics Holdings Inc Stock (ARCT) Company Profile
Nome
Arcturus Therapeutics Holdings Inc
Settore
Industria
Telefono
(858) 900-2660
Indirizzo
10628 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Confronta ARCT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ARCT
Arcturus Therapeutics Holdings Inc
|
16.41 | 444.50M | 157.75M | -29.73M | -21.00M | -1.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Arcturus Therapeutics Holdings Inc Stock (ARCT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-08-12 | Iniziato | Leerink Partners | Outperform |
| 2023-12-13 | Iniziato | Canaccord Genuity | Buy |
| 2023-07-24 | Iniziato | William Blair | Outperform |
| 2023-05-11 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2022-11-14 | Ripresa | Wells Fargo | Overweight |
| 2022-11-10 | Downgrade | Robert W. Baird | Neutral → Underperform |
| 2022-11-03 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-11-02 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2022-08-10 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2022-07-19 | Ripresa | Cantor Fitzgerald | Overweight |
| 2022-05-11 | Aggiornamento | Robert W. Baird | Underperform → Neutral |
| 2022-04-21 | Downgrade | Citigroup | Buy → Neutral |
| 2022-01-31 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2021-08-12 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2021-08-11 | Downgrade | Goldman | Neutral → Sell |
| 2021-08-10 | Downgrade | Robert W. Baird | Neutral → Underperform |
| 2021-07-02 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-06-25 | Ripresa | Goldman | Neutral |
| 2021-06-21 | Downgrade | Barclays | Equal Weight → Underweight |
| 2021-06-04 | Ripresa | Robert W. Baird | Neutral |
| 2021-02-17 | Downgrade | B. Riley Securities | Neutral → Sell |
| 2021-01-19 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2021-01-15 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2021-01-07 | Iniziato | Wells Fargo | Overweight |
| 2020-12-29 | Downgrade | Barclays | Overweight → Equal Weight |
| 2020-12-29 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2020-12-29 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2020-12-29 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-12-23 | Downgrade | ROTH Capital | Buy → Sell |
| 2020-12-08 | Reiterato | B. Riley Securities | Buy |
| 2020-12-07 | Reiterato | B. Riley Securities | Buy |
| 2020-10-26 | Iniziato | Barclays | Overweight |
| 2020-10-06 | Iniziato | Citigroup | Buy |
| 2020-08-26 | Iniziato | Piper Sandler | Overweight |
| 2020-07-30 | Ripresa | ROTH Capital | Buy |
| 2020-07-16 | Iniziato | Raymond James | Outperform |
| 2020-07-13 | Iniziato | B. Riley FBR | Buy |
| 2020-06-09 | Downgrade | WBB Securities | Buy → Hold |
| 2020-02-11 | Iniziato | Robert W. Baird | Outperform |
| 2020-02-07 | Iniziato | Guggenheim | Buy |
| 2020-02-06 | Iniziato | Guggenheim | Buy |
| 2019-04-05 | Iniziato | H.C. Wainwright | Buy |
| 2018-09-20 | Aggiornamento | WBB Securities | Buy → Strong Buy |
| 2018-01-22 | Iniziato | Chardan Capital Markets | Buy |
Mostra tutto
Arcturus Therapeutics Holdings Inc Borsa (ARCT) Ultime notizie
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Sees Significant Increase in Short Interest - Defense World
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $66.75 Consensus Target Price from Analysts - MarketBeat
Hennion & Walsh Asset Management Inc. Acquires 47,824 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - MarketBeat
Arcturus Therapeutics (NASDAQ:ARCT) Earns Buy Rating from HC Wainwright - Defense World
Arcturus Therapeutics (NASDAQ:ARCT) Receives Buy Rating from HC Wainwright - MarketBeat
Arcturus Therapeutics launches Phase I Avian Influenza trials in US - Yahoo Finance
Arcturus Launches Phase 1 Trial for Next-Gen H5N1 Flu Vaccine with BARDA Funding - StockTitan
Arcturus Therapeutics Holdings Inc (ARCT) Recovers 32.52% From Low: Are We There Yet? - Stocks Register
HC Wainwright Reiterates Buy Rating for Arcturus Therapeutics (NASDAQ:ARCT) - Defense World
Arcturus Therapeutics (NASDAQ:ARCT) Stock Price Down 8.6%Should You Sell? - MarketBeat
Arcturus Therapeutics' SWOT analysis: sa-mRNA stock poised for growth amid challenges - Investing.com India
Arcturus up 9% as phase 2 dosing begins for mRNA asset for cystic fibrosis - MSN
Arcturus Therapeutics (NASDAQ:ARCT) Trading 5.9% HigherWhat's Next? - MarketBeat
Arcturus Therapeutics' (ARCT) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Arcturus Therapeutics Announces Initiation of Dosing in Phase 2 Multiple Ascending Dose Studies for Cystic Fibrosis (CF) and Ornithine Transcarbamylase (OTC) Deficiency - Business Wire
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Shares Acquired by Geode Capital Management LLC - Defense World
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $66.75 Consensus Price Target from Analysts - Defense World
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Stock Holdings Increased by Franklin Resources Inc. - Defense World
Franklin Resources Inc. Acquires 36,714 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - MarketBeat
Head-To-Head Survey: Zymeworks (NYSE:ZYME) versus Arcturus Therapeutics (NASDAQ:ARCT) - Defense World
High Growth Tech Stocks Including Arcturus Therapeutics Holdings And Two Others - Simply Wall St
State Street Corp Sells 50,883 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - MarketBeat
We're Not Very Worried About Arcturus Therapeutics Holdings' (NASDAQ:ARCT) Cash Burn Rate - Yahoo Finance
Arcturus Therapeutics stock hits 52-week low at $14.82 - Investing.com India
Wellington Management Group LLP Lowers Stake in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - MarketBeat
HC Wainwright Reiterates “Buy” Rating for Arcturus Therapeutics (NASDAQ:ARCT) - Defense World
Arcturus Therapeutics stock hits 52-week low at $14.82 By Investing.com - Investing.com Canada
Arcturus Therapeutics (NASDAQ:ARCT) Given “Overweight” Rating at Cantor Fitzgerald - Defense World
Arcturus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - StockTitan
Arcturus Therapeutics' SWOT analysis: mRNA vaccine stock faces pivotal year - Investing.com
Cantor Fitzgerald Reaffirms "Overweight" Rating for Arcturus Therapeutics (NASDAQ:ARCT) - MarketBeat
BNP Paribas Financial Markets Raises Holdings in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World
Arcturus Therapeutics Holdings (NASDAQ:ARCT shareholders incur further losses as stock declines 9.8% this week, taking three-year losses to 63% - Simply Wall St
Fmr LLC Sells 112,516 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - MarketBeat
Why Arcturus Therapeutics (ARCT) Is the Worst ARK Stock to Buy According to Short Sellers - Yahoo Finance
10 Worst ARK Stocks To Buy According to Short Sellers - Insider Monkey
mRNA Therapeutics Market Size to Hit USD 48.65 Billion by 2032 due to Advances in Cancer Treatment and Expanding mRNA Vaccine Applications | Research by SNS Insider - GlobeNewswire Inc.
Arcturus Therapeutics (NASDAQ:ARCT) Shares Up 13.3%Here's Why - MarketBeat
Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics' Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma - The Eastern Progress Online
Arcturus Therapeutics' SWOT analysis: vaccine maker's stock faces challenges, opportunities - Investing.com Nigeria
Portolan Capital Management LLC Sells 355,763 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - MarketBeat
Arcturus Therapeutics Holdings Inc Azioni (ARCT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.81%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):